{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:18Z","timestamp":1788306558916,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>In February 2015, two unlinked culture-confirmed cases of <jats:italic toggle=\"yes\">Neisseria meningitidis<\/jats:italic> serogroup B (MenB) disease occurred at a local college in Rhode Island (\u201ccollege X\u201d) within 3 days. This represented a 489-fold increase in the incidence of MenB disease, and an outbreak was declared. For the first time, bivalent rLP2086 (Trumenba<jats:sup>\u00ae<\/jats:sup>) was selected as a mandatory intervention response. A mass vaccination clinic was coordinated, which provided a unique opportunity to collect safety data in a real-world population of college-age participants. Though the Advisory Committee on Immunization Practices recommends MenB vaccination for college-age individuals (16\u201323 year olds), there is limited quantifiable safety data available for this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The Dillman total design survey method was used. Adverse events of bivalent rLP2086 were solicited and quantified retrospectively 2\u20134 months following each dose of vaccine. Safety data from six clinical trials were used as comparison tools.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The most commonly reported adverse event following vaccination was injection site pain. Reported rates of injection site pain, fatigue, myalgia, fever, and chills were similar than those reported in clinical trials. Reported rates of headache were lower than in clinical trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This study is the first to examine adverse events of bivalent rLP2086 in a real-world setting where more than 90% of a college-age population was vaccinated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001742","type":"journal-article","created":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T00:39:18Z","timestamp":1503448758000},"page":"e13-e19","source":"Crossref","is-referenced-by-count":23,"title":["Adverse Events Following Vaccination With Bivalent rLP2086 (Trumenba\u00ae): An Observational, Longitudinal Study During a College Outbreak and a Systematic Review"],"prefix":"10.1097","volume":"37","author":[{"given":"Theresa M.","family":"Fiorito","sequence":"first","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grayson L.","family":"Baird","sequence":"additional","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Alexander-Scott","sequence":"additional","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Bornschein","sequence":"additional","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Kelleher","sequence":"additional","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Du","sequence":"additional","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope H.","family":"Dennehy","sequence":"additional","affiliation":[{"name":"Providence College Student Health Center, Providence, RI."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230913","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.15585\/mmwr.mm6441a3","article-title":"Use of serogroup B meningococcal vaccines in adolescents and young adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"MacNeil","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R2-20230913","first-page":"608","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: Recommendations of the Advisory Committee on Immunization Practices, 2015.","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R3-20230913","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u00ae).","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad Med"},{"key":"R4-20230913","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: Immunological, functional and structural characterization of the antigens.","volume":"30 Suppl 2","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"R5-20230913","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1016\/j.vaccine.2016.04.009","article-title":"Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB.","volume":"34","author":"Budroni","year":"2016","journal-title":"Vaccine"},{"key":"R6-20230913","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage.","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"R7-20230913","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.1016\/j.vaccine.2006.03.091","article-title":"Neisseria meningitidis group B correlates of protection and assay standardization\u2014international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.","volume":"24","author":"Borrow","year":"2006","journal-title":"Vaccine"},{"key":"R8-20230913","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S2049-0801(13)70037-2","article-title":"The long road to an effective vaccine for meningococcus group B (MenB).","volume":"2","author":"Shea","year":"2013","journal-title":"Ann Med Surg (Lond)"},{"key":"R9-20230913","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","article-title":"Neisseria meningitidis serogroup B vaccine development.","volume":"57","author":"Caesar","year":"2013","journal-title":"Microb Pathog"},{"key":"R11-20230913","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/IPC.0000000000000197","article-title":"Addressing the challenges of serogroup B meningococcal disease outbreaks on campuses.","volume":"22","author":"Schaffner","year":"2014","journal-title":"Infect Dis Clin Prac"},{"key":"R13-20230913","doi-asserted-by":"crossref","first-page":"D32","DOI":"10.1016\/j.vaccine.2015.05.101","article-title":"Vaccines for prevention of group B meningococcal disease: Not your father\u2019s vaccines.","volume":"33 Suppl 4","author":"Harrison","year":"2015","journal-title":"Vaccine"},{"key":"R14-20230913","first-page":"606","article-title":"Serogroup B meningococcal disease outbreak and carriage evaluation at a college\u2014Rhode Island, 2015.","volume":"64","author":"Soeters","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"R15-20230913","doi-asserted-by":"crossref","first-page":"S447","DOI":"10.1093\/ofid\/ofv133.1422","article-title":"Rapid response to a Rhode Island college outbreak of meningococcal serogroup B disease: Nation\u2019s first widespread use of Trumenba\u00ae vaccine.","volume":"2","author":"Fiorito","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R16-20230913","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jpids\/piv039","article-title":"Meningococcal serogroup B bivalent rLP2086 vaccine elicits broad and robust serum bactericidal responses in healthy adolescents.","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R17-20230913","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/jpids\/piv064","article-title":"Immunogenicity, safety, and tolerability of bivalent rLP2086 meningococcal group B vaccine administered concomitantly with diphtheria, tetanus, and acellular pertussis and inactivated poliomyelitis vaccines to healthy adolescents.","volume":"5","author":"Vesikari","year":"2016","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R18-20230913","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/INF.0b013e31826327e4","article-title":"Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18-36 months: a phase 1 randomized-controlled clinical trial.","volume":"31","author":"Marshall","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"R19-20230913","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(12)70087-7","article-title":"Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: A randomised, single-blind, placebo-controlled, phase 2 trial.","volume":"12","author":"Richmond","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R20-20230913","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1016\/j.vaccine.2012.07.065","article-title":"A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: Results of a randomised, controlled, dose-escalation phase 1 trial.","volume":"30","author":"Richmond","year":"2012","journal-title":"Vaccine"},{"key":"R21-20230913","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1097\/INF.0000000000001124","article-title":"A phase 2, randomized, active-controlled, observer-blinded study to assess the immunogenicity, tolerability and safety of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with tetanus, diphtheria and acellular pertussis vaccine and serogroup A, C, Y and W-135 meningococcal conjugate vaccine in healthy US adolescents.","volume":"35","author":"Muse","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20230913","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/INF.0000000000001072","article-title":"Immunogenicity, tolerability and safety in adolescents of bivalent rLP2086, a meningococcal serogroup B vaccine, coadministered with quadrivalent human papilloma virus vaccine.","volume":"35","author":"Senders","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R23-20230913","doi-asserted-by":"crossref","first-page":"888","DOI":"10.4161\/hv.19983","article-title":"A phase 1, randomized, open-label, active-controlled trial to assess the safety of a meningococcal serogroup B bivalent rLP2086 vaccine in healthy adults.","volume":"8","author":"Sheldon","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R24-20230913","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.vaccine.2013.01.021","article-title":"A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults.","volume":"31","author":"Marshall","year":"2013","journal-title":"Vaccine"},{"key":"R25-20230913","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.vaccine.2016.01.044","article-title":"A phase 3, randomized, active-controlled study to assess the safety and tolerability of meningococcal serogroup B vaccine bivalent rLP2086 in healthy adolescents and young adults.","volume":"34","author":"Ostergaard","year":"2016","journal-title":"Vaccine"},{"key":"R26-20230913","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.vaccine.2015.12.016","article-title":"Immunogenicity, safety, and tolerability of the meningococcal serogroup B bivalent rLP2086 vaccine in adult laboratory workers.","volume":"34","author":"Reiner","year":"2016","journal-title":"Vaccine"},{"key":"R27-20230913","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1016\/j.vaccine.2014.07.049","article-title":"A randomized, phase \u00bd trial of the safety, tolerability, and immunogenicity of bivalent rLP2086 meningococcal B vaccine in healthy infants.","volume":"32","author":"Martinon-Torres","year":"2014","journal-title":"Vaccine"},{"key":"R28-20230913","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/INF.0b013e31827b0d24","article-title":"A randomized, controlled, phase \u00bd trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents.","volume":"32","author":"Nissen","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R30-20230913","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1146\/annurev.so.17.080191.001301","article-title":"The design and administration of mail surveys.","volume":"17","author":"Dillman","year":"1991","journal-title":"Ann Rev Soc"},{"key":"R32-20230913","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R35-20230913","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/269211","article-title":"The effect of monetary incentives and follow-up mailings on the response rate and response quality in mail surveys.","volume":"54","author":"James","year":"1990","journal-title":"Public Opin Q"},{"key":"R36-20230913","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/07448480009596267","article-title":"Identifying male college students\u2019 perceived health needs, barriers to seeking help, and recommendations to help men adopt healthier lifestyles.","volume":"48","author":"Davies","year":"2000","journal-title":"J Am Coll Health"},{"key":"R37-20230913","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/07448480209596021","article-title":"Social stigma and negative consequences: Factors that influence college students\u2019 decisions to seek testing for sexually transmitted infections.","volume":"50","author":"Barth","year":"2002","journal-title":"J Am Coll Health"},{"key":"R38-20230913","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s11229-014-0434-1","article-title":"On the rationality of pluralistic ignorance.","volume":"191","author":"Bjerring","year":"2014","journal-title":"Synthese"},{"key":"R39-20230913","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/NSS.S62907","article-title":"Causes and consequences of sleepiness among college students.","volume":"6","author":"Hershner","year":"2014","journal-title":"Nat Sci Sleep"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201801000-00022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:15:26Z","timestamp":1694628926000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201801000-00022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001742","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}